vs
普立万（AVNT）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是普立万的1.0倍（$772.1M vs $760.6M），Revvity净利率更高（12.7% vs 2.2%，领先10.5%），Revvity同比增速更快（5.9% vs 1.9%），Revvity自由现金流更多（$161.8M vs $125.4M），过去两年Revvity的营收复合增速更高（9.0% vs -4.2%）
普立万公司是一家全球性材料解决方案供应商，总部位于美国俄亥俄州埃文湖，全球员工约9000人。主营产品涵盖色母粒、先进复合材料、功能添加剂以及工程材料，为多行业客户提供定制化的材料相关技术支持与解决方案。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
AVNT vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.0倍
$760.6M
营收增速更快
RVTY
高出4.0%
1.9%
净利率更高
RVTY
高出10.5%
2.2%
自由现金流更多
RVTY
多$36.4M
$125.4M
两年增速更快
RVTY
近两年复合增速
-4.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $760.6M | $772.1M |
| 净利润 | $16.9M | $98.4M |
| 毛利率 | 30.2% | — |
| 营业利润率 | 5.2% | 14.5% |
| 净利率 | 2.2% | 12.7% |
| 营收同比 | 1.9% | 5.9% |
| 净利润同比 | -65.0% | 3.9% |
| 每股收益（稀释后） | $0.18 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVNTRVTY
| Q4 25 | $760.6M | $772.1M | ||
| Q3 25 | $806.5M | $698.9M | ||
| Q2 25 | $866.5M | $720.3M | ||
| Q1 25 | $826.6M | $664.8M | ||
| Q4 24 | $746.5M | $729.4M | ||
| Q3 24 | $815.2M | $684.0M | ||
| Q2 24 | $849.7M | $691.7M | ||
| Q1 24 | $829.0M | $649.9M |
净利润AVNTRVTY
| Q4 25 | $16.9M | $98.4M | ||
| Q3 25 | $32.6M | $46.7M | ||
| Q2 25 | $52.6M | $53.9M | ||
| Q1 25 | $-20.2M | $42.2M | ||
| Q4 24 | $48.3M | $94.6M | ||
| Q3 24 | $38.2M | $94.4M | ||
| Q2 24 | $33.6M | $55.4M | ||
| Q1 24 | $49.4M | $26.0M |
毛利率AVNTRVTY
| Q4 25 | 30.2% | — | ||
| Q3 25 | 30.4% | 53.6% | ||
| Q2 25 | 32.1% | 54.5% | ||
| Q1 25 | 31.8% | 56.5% | ||
| Q4 24 | 34.8% | — | ||
| Q3 24 | 32.1% | 56.3% | ||
| Q2 24 | 30.3% | 55.7% | ||
| Q1 24 | 33.6% | 54.6% |
营业利润率AVNTRVTY
| Q4 25 | 5.2% | 14.5% | ||
| Q3 25 | 8.3% | 11.7% | ||
| Q2 25 | 11.1% | 12.6% | ||
| Q1 25 | 0.1% | 10.9% | ||
| Q4 24 | 11.5% | 16.3% | ||
| Q3 24 | 9.5% | 14.3% | ||
| Q2 24 | 8.5% | 12.4% | ||
| Q1 24 | 11.3% | 6.8% |
净利率AVNTRVTY
| Q4 25 | 2.2% | 12.7% | ||
| Q3 25 | 4.0% | 6.7% | ||
| Q2 25 | 6.1% | 7.5% | ||
| Q1 25 | -2.4% | 6.4% | ||
| Q4 24 | 6.5% | 13.0% | ||
| Q3 24 | 4.7% | 13.8% | ||
| Q2 24 | 4.0% | 8.0% | ||
| Q1 24 | 6.0% | 4.0% |
每股收益（稀释后）AVNTRVTY
| Q4 25 | $0.18 | $0.86 | ||
| Q3 25 | $0.36 | $0.40 | ||
| Q2 25 | $0.57 | $0.46 | ||
| Q1 25 | $-0.22 | $0.35 | ||
| Q4 24 | $0.53 | $0.77 | ||
| Q3 24 | $0.41 | $0.77 | ||
| Q2 24 | $0.36 | $0.45 | ||
| Q1 24 | $0.54 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | $1.9B | — |
| 股东权益账面价值 | $2.4B | $7.3B |
| 总资产 | $6.0B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.81× | — |
8季度趋势，按日历期对齐
现金及短期投资AVNTRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
总债务AVNTRVTY
| Q4 25 | $1.9B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.0B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.1B | — | ||
| Q1 24 | $2.1B | — |
股东权益AVNTRVTY
| Q4 25 | $2.4B | $7.3B | ||
| Q3 25 | $2.4B | $7.4B | ||
| Q2 25 | $2.4B | $7.6B | ||
| Q1 25 | $2.3B | $7.6B | ||
| Q4 24 | $2.3B | $7.7B | ||
| Q3 24 | $2.4B | $7.9B | ||
| Q2 24 | $2.3B | $7.9B | ||
| Q1 24 | $2.3B | $7.8B |
总资产AVNTRVTY
| Q4 25 | $6.0B | $12.2B | ||
| Q3 25 | $6.1B | $12.1B | ||
| Q2 25 | $6.1B | $12.4B | ||
| Q1 25 | $5.8B | $12.4B | ||
| Q4 24 | $5.8B | $12.4B | ||
| Q3 24 | $6.0B | $12.8B | ||
| Q2 24 | $5.9B | $13.4B | ||
| Q1 24 | $5.9B | $13.4B |
负债/权益比AVNTRVTY
| Q4 25 | 0.81× | — | ||
| Q3 25 | 0.83× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 0.90× | — | ||
| Q4 24 | 0.89× | — | ||
| Q3 24 | 0.88× | — | ||
| Q2 24 | 0.90× | — | ||
| Q1 24 | 0.90× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $167.8M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $125.4M | $161.8M |
| 自由现金流率自由现金流/营收 | 16.5% | 21.0% |
| 资本支出强度资本支出/营收 | 5.6% | 2.6% |
| 现金转化率经营现金流/净利润 | 9.93× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $195.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流AVNTRVTY
| Q4 25 | $167.8M | $182.0M | ||
| Q3 25 | $72.1M | $138.5M | ||
| Q2 25 | $112.8M | $134.3M | ||
| Q1 25 | $-51.1M | $128.2M | ||
| Q4 24 | $122.6M | $174.2M | ||
| Q3 24 | $71.1M | $147.9M | ||
| Q2 24 | $105.9M | $158.6M | ||
| Q1 24 | $-42.8M | $147.6M |
自由现金流AVNTRVTY
| Q4 25 | $125.4M | $161.8M | ||
| Q3 25 | $47.4M | $120.0M | ||
| Q2 25 | $85.8M | $115.5M | ||
| Q1 25 | $-63.6M | $112.2M | ||
| Q4 24 | $81.5M | $149.8M | ||
| Q3 24 | $46.1M | $125.6M | ||
| Q2 24 | $74.5M | $136.6M | ||
| Q1 24 | $-67.2M | $129.7M |
自由现金流率AVNTRVTY
| Q4 25 | 16.5% | 21.0% | ||
| Q3 25 | 5.9% | 17.2% | ||
| Q2 25 | 9.9% | 16.0% | ||
| Q1 25 | -7.7% | 16.9% | ||
| Q4 24 | 10.9% | 20.5% | ||
| Q3 24 | 5.7% | 18.4% | ||
| Q2 24 | 8.8% | 19.7% | ||
| Q1 24 | -8.1% | 20.0% |
资本支出强度AVNTRVTY
| Q4 25 | 5.6% | 2.6% | ||
| Q3 25 | 3.1% | 2.6% | ||
| Q2 25 | 3.1% | 2.6% | ||
| Q1 25 | 1.5% | 2.4% | ||
| Q4 24 | 5.5% | 3.4% | ||
| Q3 24 | 3.1% | 3.3% | ||
| Q2 24 | 3.7% | 3.2% | ||
| Q1 24 | 2.9% | 2.7% |
现金转化率AVNTRVTY
| Q4 25 | 9.93× | 1.85× | ||
| Q3 25 | 2.21× | 2.97× | ||
| Q2 25 | 2.14× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 2.54× | 1.84× | ||
| Q3 24 | 1.86× | 1.57× | ||
| Q2 24 | 3.15× | 2.87× | ||
| Q1 24 | -0.87× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVNT
| Color Additives And Inks | $466.0M | 61% |
| Specialty Engineered Materials | $295.5M | 39% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
